Predicting Blood Clot Risks in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors An Observational Study on Venous and Arterial Thromboembolism

What this Trial Is About

Researchers are studying lung cancer patients receiving immune checkpoint inhibitors ICIs to understand how often venous thromboembolism VTE and arterial thromboembolism ATE occur, what risk factors and biomarkers are involved, and how these events affect patient outcomes. The study aims to identify specific biomarkers linked to thrombotic events and develop a risk prediction model to support personalized prevention and treatment in clinical care. This observational study divides participants into groups based on whether they experience ICI-associated VTE or ATE. Researchers compare patient characteristics and biomarkers between those with and without these thrombotic events to find new markers and risk factors. Data collection begins at the first dose of ICIs and continues until death, the start of other cancer treatments, or three months after the last ICI dose, with follow-up lasting up to 96 months. During the study, participants are monitored for thrombotic events and their impact on progression-free survival, overall survival, and response to treatment. Key outcomes are assessed through clinical data and biomarkers collected over time. The research team tracks these outcomes from treatment start through a long-term follow-up period, aiming to improve understanding of thrombosis risks in lung cancer patients receiving ICIs.

Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors